Affinity labelling of frog brain opioid receptors by dynorphin ((1-10)) chloromethyl ketone

Neuropeptides

Volumn 31, Issue 1, 1997, Pages 52-59

  Benyhe, S ^a   Ketevan, A ^a   Simon, J ^a   Hepp, J ^b   Medzihradszky, K ^b   Borsodi, A ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROMORPHINE H 3; DYNORPHIN DERIVATIVE; ETHYLKETAZOCINE H 3; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; RADIOLIGAND; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AFFINITY LABELING; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; FROG; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALIA; ANURA; RANA ESCULENTA;

EID: 0031058301     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(97)90020-2     Document Type: Article

References (34)

1. 5-enkephalin chloromethyl ketone. Life Sci 1983; 32: 2777-2784.
2. 5-enkephalin chloromethyl ketone: I. Binding characteristics in rat brain membranes. Life Sci 1987; 41: 177-184.
3. Benyhe S, Hepp J, Szücs M et al. Irreversible labelling of rat brain opioid receptors by enkephalin chloromethyl ketones. Neuropeptides 1986; 8: 173-184.
4. Benyhe S, Hepp J, Simon J, Borsodi A, Medzihradszky K, Wollemann M. Tyr-D-Ala-Gly-(Me)Phe-chloromethyl ketone: a μ specific affinity label for the opioid receptor. Neuropeptides 1987; 9: 225-235.
5. 2-Leu-enkephalin-chloromethyl ketone of high specific activity. J Label Comp Radiopharm 1987; 24: 859-866.
6. 3H-Tyr-D-Ala-Gly-N(Me)Phe chloromethyl ketone - an opioid affinity label. Neuropeptides 1988; 12: 135-139.
7. 3H]-Tyr-D-Ala-Gly-(Me)Phe chloromethyl ketone. Life Sci 1991; 48: 1757-1762.
8. 3H]-Tyr-D-Ala-Gly-(Me) Phe chloromethyl ketone. Life Sci 1991; 48: 1763-1768.
9. Rónai A Z, Hepp J, Magyar A, Borsodi A, Medzihradszky K. Design of opioid peptides for a potential delta-receptor affinity label function: comparison with the mu-specific Tyr-D-Ala-Gly-(Me)Phe-chloromethyl ketone. Pharmacology 1994; 49: 121-131.
10. Pelton J T, Johnston R B, Balk J L, Schmidt C J, Roche E B. Synthesis and biological activity of chloromethyl ketones of leucine enkephalin. Biochem Biophys Res Commun 1980; 97: 1391-1398.
11. Newman E L, Barnard E A. Identification of an opioid receptor subunit carrying the mu-binding site. Biochemistry 1984; 23: 5385-5389.
12. Simon J, Szücs M, Benyhe S, Borsodi A, Zeman P, Wollemann M. Solubilization and characterization of opioid binding sites from frog (Rana esculenta) brain. J Neurochem 1984; 43: 957-963.
13. 2 opioid binding sites in frog (Rana esculenta) brain membrane preparation. Neurochem Res 1990; 15: 899-904.
14. 1-8 binding sites in frog (Rana esculenta) brain membranes. Neuropeptides 1994; 26: 359-364.
15. Simon J, Benyhe S, Hepp J et al. Method for isolation of kappa-opioid binding sites by dynorphin affinity chromatography. J Neurosci Res 1990; 25: 549-555.
16. 5-enkephalin chloromethyl ketone: II. Binding characteristics in frog brain membranes. Life Sci 1987; 41: 185-193.
17. Wollemann M, Benyhe S, Simon J. Minireview: the kappa-opioid receptor: evidence for the different subtypes. Life Sci 1993; 52: 599-611.
18. 2 opioid receptors. Proc Natl Acad Sci USA 1988; 85: 4061-4065.
19. Attali B, Gouarderes C, Mazarguil H, Audigier Y, Cros J. Evidence for multiple kappa binding sites by use of opioid peptides in the guinea-pig lumbo-sacral spinal cord. Neuropeptides 1982; 3: 53-64.
20. 5-enkephalin binding. Neurochem Res 1985; 10: 627-635.
21. 3H]dihydromorphine of high molar activity and its application in opiate receptor binding experiments. Radiochem Radioanal Lett 1982; 56: 209-216.
22. Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
23. Munson P J, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand binding system. Anal Biochem 1980; 107: 220-239.
24. Munson P J. A user's guide to LIGAND data analysis and curvefitting for ligand binding experiments. J M Coburn Systex, Beltsville, MD, 1987: 1-107.
25. 3H]ethylketocyclazocine. Life Sci 1992; 51: 1647-1655.
26. 3 subtype. J Pharmacol Exp Ther 1989; 251:461-468.
27. Schwyzer R. Molecular mechanism of opioid receptor selection. Biochemistry 1986; 25: 6335-6342.
28. Faden A, Jacobs T P. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action. Br J Pharmacol 1984; 82: 271-276.
29. 7 binding to opioid receptors in frog brain membrane preparations. J Neurochem 1994; 1460-1465.
30. Mansour A, Hoversten M T, Taylor L P, Watson S J, Akil H. The cloned μ, δ and κ receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 1995; 700: 89-98.
31. Chavkin C, Goldstein A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc Natl Acad Sci USA 1981; 78: 6543-6547.
32. Chang A-C, Takemori A E, Ojala W H, Gleason W B, Portoghese P S. Kappa opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists. J Med Chem 1994; 37: 4490-4498.
33. Matsueda R, Koike K, Takayanagi I. Design and synthesis of highly potent and specific dynorphin derivatives for affinity labeling of kappa opioid receptors. Chem Pharm Bull (Tokyo) 1993; 41: 1312-1314.
34. 1-11 In: Cros J, Meunier J C, Hamon M. Advances in the biosciences 75, Progress in opioid research. Oxford: Pergamon Press, 1989: 21-24.